Merck & Company Says It Received Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Portfolio Pulse from Benzinga Newsdesk
Merck & Company has received a positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) for its drug KEYTRUDA, in combination with chemotherapy, as a first-line treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma expressing PD-L1 (CPS ≥1).
October 13, 2023 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has received a positive opinion from the EU CHMP, potentially expanding its market in the EU. This could lead to increased revenues for Merck.
The positive opinion from the EU CHMP for Merck's KEYTRUDA means that the drug is one step closer to being approved for use in the EU. This could potentially expand the market for KEYTRUDA, leading to increased revenues for Merck. Therefore, this news is likely to have a positive impact on Merck's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100